SCHEMBL14239097

SCHEMBL14239097

C1=CCC2(C1)CCNC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5426324 0.85 TSHR (0.32)
SCHEMBL21829908 0.83
SCHEMBL584838 0.82 TSHR (0.37)
SCHEMBL5419554 0.80 TSHR (0.31)
SCHEMBL5418526 0.79 TSHR (0.32)
SCHEMBL473625 0.78
SCHEMBL5423967 0.76 TSHR (0.41)
SCHEMBL343237 0.76
SCHEMBL29407644 0.76
SCHEMBL303389 0.76 TSHR (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) 2024-07-18 US disclosed
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) 2024-07-18 US disclosed
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-11-09 US disclosed
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-11-09 US disclosed
US-11718620-B2 Method for treating a cancer mediated by abnormality of multi-kinases TRANSTHERA SCIENCES (NANJING), INC. (CN) 2023-08-08 US disclosed
US-11718620-B2 Method for treating a cancer mediated by abnormality of multi-kinases TRANSTHERA SCIENCES (NANJING), INC. (CN) 2023-08-08 US disclosed
WO-2023131277-A1 NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF 药捷安康(南京)科技股份有限公司 2023-07-13 WO disclosed
EP-3452484-B1 CERTAIN PROTEIN KINASE INHIBITORS FOCHON PHARMACEUTICALS LTD (CN) 2023-07-05 EP disclosed
WO-2023104074-A1 NEW USE OF KINASE INHIBITOR 药捷安康(南京)科技股份有限公司 2023-06-15 WO disclosed
US-20230174556-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-06-08 US disclosed
EP-2738156-A1 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND KBP Biosciences Co., Ltd. (CN) 2014-06-04 EP disclosed
US-20140128331-A1 C-GLYCOSIDE DERIVATIVES Xuanzhu Pharma Co., Ltd. (CN) 2014-05-08 US disclosed
US-20140128331-A1 C-GLYCOSIDE DERIVATIVES Xuanzhu Pharma Co., Ltd. (CN) 2014-05-08 US disclosed
EP-2725031-A1 C-GLYCOSIDE DERIVATIVES Xuanzhu Pharma Co., Ltd. (CN) 2014-04-30 EP disclosed
WO-2014023083-A1 PI3Kδ INHIBITOR 山东亨利医药科技有限责任公司 (CN) 2014-02-13 WO disclosed
WO-2013044865-A1 OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING 山东轩竹医药科技有限公司 (CN) 2013-04-04 WO disclosed
WO-2013013504-A1 TIGECYCLINE DERIVATIVE 山东亨利医药科技有限责任公司 (CN) 2013-01-31 WO disclosed
WO-2013013505-A1 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND 山东亨利医药科技有限责任公司 (CN) 2013-01-31 WO disclosed
WO-2013010382-A1 HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND 山东亨利医药科技有限责任公司 (CN) 2013-01-24 WO disclosed
WO-2012167606-A1 PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF 山东亨利医药科技有限责任公司 (CN) 2012-12-13 WO disclosed